SCHEMBL30329937

SCHEMBL30329937

CNc1cc(C)nc(Nc2cc3c(c(Br)c2F)OCCO3)n1

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ EGFR P00533 4/20 0.33
▸ EHMT2 Q96KQ7 6/20 0.32
▸ EHMT1 Q9H9B1 5/20 0.32
▸ ABCB1 P08183 1/20 0.32
▸ ABCC1 P33527 1/20 0.32
▸ ABCG2 Q9UNQ0 1/20 0.32
▸ IGF1R P08069 1/20 0.31
▸ NOS3 P29474 1/20 0.31
▸ NOS2 P35228 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25166080 1.00 ALDH1A1 (0.35) ALDH1A1MAPTEGFREHMT2EHMT1
SCHEMBL25166482 0.91 ALDH1A1 (0.38) ALDH1A1MAPTEHMT2EHMT1NOS3
SCHEMBL30329841 0.91 ALDH1A1 (0.38) ALDH1A1MAPTEHMT2EHMT1NOS3
SCHEMBL30329725 0.88 ALDH1A1 (0.36) ALDH1A1MAPTEHMT2EHMT1ABCB1
SCHEMBL25166700 0.88 ALDH1A1 (0.36) ALDH1A1MAPTEHMT2EHMT1ABCB1
SCHEMBL25166233 0.86 EHMT2 (0.35) ALDH1A1MAPTEHMT2EHMT1ABCB1
SCHEMBL30330078 0.86 EHMT2 (0.35) ALDH1A1MAPTEHMT2EHMT1ABCB1
SCHEMBL25166027 0.85 ALDH1A1 (0.34) ALDH1A1MAPTEHMT2EHMT1IGF1R
SCHEMBL30329850 0.85 ALDH1A1 (0.34) ALDH1A1MAPTEHMT2EHMT1IGF1R
SCHEMBL25166595 0.83 EHMT2 (0.34) ALDH1A1MAPTEHMT2EHMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 — — US disclosed
CN-118647610-A Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof 探戈医药股份有限公司 2024-09-13 — — CN disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 — — EP disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 ALDH1A1 163/4885MAPT 2171/4885EGFR 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback